Butorphanol and nalbuphine in opioid-dependent humans under a naloxone discrimination procedure

Pharmacology Biochemistry and Behavior

Volumn 71, Issue 1-2, 2002, Pages 85-96

  Oliveto, Alison ^a,b   Sevarino, Kevin ^a,b   McCance Katz, Elinore ^a,b,c   Feingold, Alan ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Butorphanol; Drug discrimination; Humans; Instructed novel response; Nalbuphine; Naloxone; Opioid dependence

Indexed keywords

BUTORPHANOL; NALBUPHINE; NALOXONE; OPIATE AGONIST; OPIATE ANTAGONIST; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DRUG DISCRIMINATION; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; DRUG SPECIFICITY; FEMALE; HUMAN; OPIATE ADDICTION; PRIORITY JOURNAL; STIMULUS RESPONSE;

ADULT; ANALYSIS OF VARIANCE; BUTORPHANOL; DISCRIMINATION (PSYCHOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MIDDLE AGED; NALBUPHINE; NALOXONE; NARCOTIC ANTAGONISTS; NARCOTICS; OPIOID-RELATED DISORDERS; QUESTIONNAIRES;

EID: 0037006015     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(01)00637-2     Document Type: Article

References (43)

1. Opioid drug discrimination in humans: Stability, specificity and relation to self-reported drug effect
2. A novel-response procedure enhances the specificity and sensitivity of a triazolam discrimination in humans
3. An experimental paradigm for studying the discriminative stimulus properties of drugs in humans
4. Drug discrimination: Behavioral, pharmacological, and molecular mechanisms of discriminative drug effects
5. The discriminative response: An elementary particle of behavior
6. Effects of clonidine and yohimbine in opioid-maintained humans under a novel-response naloxone discrimination procedure
7. Assessment of the abuse potential of morphine-like drugs (methods used in man)
8. Discriminative stimulus effects of diazepam in humans
9. Further studies on the discriminative stimulus effects of diazepam in humans
10. Assessment of opioid partial agonist activity with a three-choice hydromorphone dose-discrimination procedure
11. Drug discrimination by humans compared to nonhumans: Current status and future directions
12. Triazolam discrimination by humans under a novel-response procedure: Effects of buspirone and lorazepam
13. Nalbuphine co-administered with morphine prevents tolerance and dependence
14. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine and methylphenidate in man
15. The mu opioid irreversible antagonist beta-funaltrexamine differentiates the discriminative-stimulus effects of opioids with high and low efficacy at the mu opioid receptor
16. Acute and chronic morphine administration: Effects of mixed-action opioids in rats and squirrel monkeys responding under a schedule of food presentation
17. Caffeine drug discrimination in humans: Acquisition, specificity and correlation with self-reports
18. Pharmacological specificity of the caffeine discriminative stimulus in humans: Effects of theophylline, methylphenidate and buspirone
19. Effects of diazepam and hydromorphone in triazolam-trained humans under a novel-response drug-discrimination procedure
20. Discriminative stimulus, self-reported and cardiovascular effects of orally-administered cocaine in humans
21. Functional antagonism of the caffeine discriminative stimulus by triazolam in humans
22. Effects of D-amphetamine and caffeine in humans under a cocaine discrimination procedure
23. Naloxone discrimination in opioid-dependent humans under a novel-response discrimination procedure
24. State dependent learning and drug discriminations
25. The pharmacology of butorphanol, a 3,14-dihydroxymorphinan narcotic antagonist analgesic
26. Subjective and discriminative effects of drugs
27. Drug discrimination assessment of agonist-antagonist opioids in humans: A three-choice saline-hydromorphone-butorphanol procedure
28. Abuse liability studies of opioid agonist-antagonists in humans
29. Three-choice drug discrimination in opioid-dependent humans: Hydromorphone, naloxone and saline
30. Butorphanol-precipitated withdrawal in opioid-dependent human volunteers
31. Drug discrimination in human post-addicts: Agonist-antagonist opioids
32. Antagonist effects of nalbuphine in opioid-dependent human volunteers
33. Discrimination of butorphanol and nalbuphine in opioid-dependent subjects
34. Discrimination of agonist-antagonist opioids in humans trained on a two-choice saline-hydromorphone discrimination
35. Buprenorphine, morphine and naloxone effects during ascending morphine maintenance in humans
36. Relationship between the discriminative-stimulus properties and subjective effects of drugs
37. The novel-response procedure in humans
38. Flumazenil discrimination by humans under a two-response and a novel-response procedure
39. Measures of stimulus generalization in drug discrimination experiments
40. Discriminative-stimulus effects of nalbuphine in nontreated and morphine-treated pigeons
41. Discriminative-stimulus profiles of psychoactive drugs
42. The time is ripe for an experimental analysis of measurement issues
43. Discriminative-stimulus effects of morphine: Effects of training dose on agonist and antagonist effects of mu opioids